The SFB/TRR219 Consortium “Mechanisms of Cardiovascular Complications in Chronic Kidney Disease” is funded by the German Research Foundation
Patients with chronic kidney disease (CKD) exhibit a massively increased risk for cardiovascular events: 50% of patients with CKD stage 4-5 suffer from cardiovascular disease (CVD), and cardiovascular mortality accounts for ~40-50% of all deaths in patients with CKD stage 4 as well as patients with end-stage renal disease, compared with 26% in controls with normal kidney function. Alterations in the circulation as well as in the myocardium crucially contribute to the increased cardiovascular risk in patients suffering from CKD. However, the molecular mechanisms as well as the mediators involved are largely unexplored.
By collaborative and translational research based on existing interactions between groups of different clinical and methodological expertise, we pursue an overall long-term goal to gain understanding of the renal and cardiovascular interactions. This may contribute to the development of novel treatment strategies to decrease cardiovascular risk in CKD patients.
Alterations in the circulation as well as in the myocardium crucially contribute to the increased cardiovascular risk in patients with CKD.
Funding period: 2018-2021
University Hospital RWTH Aachen & Saarland University
Spokesperson: Prof. Dr. rer. nat. Joachim Jankowski
(University Hospital RWTH Aachen)
Deputy spokesperson: Prof. Dr. med. Danilo Fliser